← Back to Clinical Trials
Recruiting NCT07462091

NCT07462091 Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07462091
Status Recruiting
Phase
Sponsor Northern Jiangsu People's Hospital
Condition Cirrhosis
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2026-03-25
Primary Completion 2027-03-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2026-03-25 with a primary completion date of 2027-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aimed to evaluate the effectiveness and safety of vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection, and to assess its impact on postoperative digestive complications and quality of life.

Eligibility Criteria

Inclusion Criteria: 1. A clinical, radiological or histologic diagnosis of cirrhosis of any etiology 2. Splenomegaly with secondary hypersplenism 3. Bleeding portal hypertension 4. No evidence of portal vein system thrombosis by ultrasound evaluation and angio-CT 5. Informed consent to participate in the study Exclusion Criteria: 1. Delayed gastric emptying 2. Diarrhea 3. Hepatocellular carcinoma or any other malignancy, 4. Hypercoagulable state other than the liver disease related 5. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs. 6. Child - Pugh C 7. Recent peptic ulcer disease 8. History of Hemorrhagic stroke 9. Pregnancy. 10. Uncontrolled Hypertension 11. Human immunodeficiency virus (HIV) infection

Contact & Investigator

Central Contact

Guo-Qing Jiang, MD

✉ jgqing2003@hotmail.com

📞 +86-514-87373272

Principal Investigator

Dou-Sheng Bai, MD

STUDY CHAIR

Clinical Medical College, Yangzhou University

Frequently Asked Questions

Who can join the NCT07462091 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07462091 currently recruiting?

Yes, NCT07462091 is actively recruiting participants. Contact the research team at jgqing2003@hotmail.com for enrollment information.

Where is the NCT07462091 trial being conducted?

This trial is being conducted at Yangzhou, China, Yangzhou, China.

Who is sponsoring the NCT07462091 clinical trial?

NCT07462091 is sponsored by Northern Jiangsu People's Hospital. The principal investigator is Dou-Sheng Bai, MD at Clinical Medical College, Yangzhou University. The trial plans to enroll 15 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology